Brian Goff - Net Worth and Insider Trading

Brian Goff Net Worth

The estimated net worth of Brian Goff is at least $8 Million dollars as of 2024-05-02. Brian Goff is the EVP & Chief Commercial Officer of Alexion Pharmaceuticals Inc and owns about 36,257 shares of Alexion Pharmaceuticals Inc (ALXN) stock worth over $7 Million. Brian Goff is also the CEO of Agios Pharmaceuticals Inc and owns about 49,436 shares of Agios Pharmaceuticals Inc (AGIO) stock worth over $2 Million. Details can be seen in Brian Goff's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Brian Goff has not made any transactions after 2024-01-24 and currently still holds the listed stock(s).

Transaction Summary of Brian Goff

Brian Goff Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Brian Goff owns 3 companies in total, including Alexion Pharmaceuticals Inc (ALXN) , Baxalta Inc (BXLT) , and Agios Pharmaceuticals Inc (AGIO) .

Click here to see the complete history of Brian Goff’s form 4 insider trades.

Insider Ownership Summary of Brian Goff

Ticker	Comapny	Transaction Date	Type of Owner
ALXN	Alexion Pharmaceuticals Inc	2020-06-08	EVP & Chief Commercial Officer
BXLT	Baxalta Inc	2016-06-03	EVP and President & Hematology
AGIO	Agios Pharmaceuticals Inc	2024-01-24	director & Chief Executive Officer

Brian Goff Latest Holdings Summary

Brian Goff currently owns a total of 2 stocks. Among these stocks, Brian Goff owns 36,257 shares of Alexion Pharmaceuticals Inc (ALXN) as of June 8, 2018, with a value of $7 Million and a weighting of 79.37%. Brian Goff also owns 49,436 shares of Agios Pharmaceuticals Inc (AGIO) as of January 24, 2024, with a value of $2 Million and a weighting of 20.63%.

Latest Holdings of Brian Goff

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ALXN	Alexion Pharmaceuticals Inc	2018-06-08	36,257	182.50	6,616,903
AGIO	Agios Pharmaceuticals Inc	2024-01-24	49,436	34.78	1,719,384

Holding Weightings of Brian Goff

Brian Goff Form 4 Trading Tracker

According to the SEC Form 4 filings, Brian Goff has made a total of 0 transactions in Alexion Pharmaceuticals Inc (ALXN) over the past 5 years. The most-recent trade in Alexion Pharmaceuticals Inc is the sale of 1,645 shares on June 8, 2018, which brought Brian Goff around $194,982.

According to the SEC Form 4 filings, Brian Goff has made a total of 4 transactions in Agios Pharmaceuticals Inc (AGIO) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Agios Pharmaceuticals Inc is the sale of 7,635 shares on January 24, 2024, which brought Brian Goff around $165,221.

Insider Trading History of Brian Goff

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Brian Goff Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Brian Goff Ownership Network

Ownership Network List of Brian Goff

No Data

Ownership Network Relation of Brian Goff

Brian Goff Owned Company Details

What does Alexion Pharmaceuticals Inc do?

Who are the key executives at Alexion Pharmaceuticals Inc?

Brian Goff is the EVP & Chief Commercial Officer of Alexion Pharmaceuticals Inc. Other key executives at Alexion Pharmaceuticals Inc include SVP & Controller & CAO Daniel Bazarko , EVP & CCAO Tanisha Carino , and EVP & Research & Development John J Orloff .

Alexion Pharmaceuticals Inc (ALXN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Alexion Pharmaceuticals Inc (ALXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Alexion Pharmaceuticals Inc (ALXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Alexion Pharmaceuticals Inc (ALXN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alexion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Baxalta Inc do?

Who are the key executives at Baxalta Inc?

Brian Goff is the EVP and President & Hematology of Baxalta Inc. Other key executives at Baxalta Inc include EVP & Head of Human Resources Anne-marie Law , See Remarks John J Orloff , and director & President and CEO Ludwig Hantson .

Baxalta Inc (BXLT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Baxalta Inc (BXLT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Baxalta Inc (BXLT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Baxalta Inc (BXLT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Baxalta Inc Insider Transactions

No Available Data

What does Agios Pharmaceuticals Inc do?

Who are the key executives at Agios Pharmaceuticals Inc?

Brian Goff is the director & Chief Executive Officer of Agios Pharmaceuticals Inc. Other key executives at Agios Pharmaceuticals Inc include Chief Legal Officer James William Burns , Chief Medical Officer Sarah Gheuens , and Principal Accounting Officer Washburn Theodore James Jr. .

Agios Pharmaceuticals Inc (AGIO) Insider Trades Summary

Over the past 18 months, Brian Goff made 4 insider transaction in Agios Pharmaceuticals Inc (AGIO) with a net sale of 41,328. Other recent insider transactions involving Agios Pharmaceuticals Inc (AGIO) include a net sale of 205,692 shares made by David P Schenkein , a net sale of 8,791 shares made by Washburn Theodore James Jr. , and a net sale of 14,160 shares made by James William Burns .

In summary, during the past 3 months, insiders sold 93,495 shares of Agios Pharmaceuticals Inc (AGIO) in total and bought 0 shares, with a net sale of 93,495 shares. During the past 18 months, 358,881 shares of Agios Pharmaceuticals Inc (AGIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 358,881 shares.

Agios Pharmaceuticals Inc (AGIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Agios Pharmaceuticals Inc Insider Transactions

No Available Data

Brian Goff Mailing Address

Above is the net worth, insider trading, and ownership report for Brian Goff. You might contact Brian Goff via mailing address: C/o Alexion Pharmaceuticals, Inc, 100 College Street, New Haven Ct 06510.

Discussions on Brian Goff

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.